Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE: Sipuleucel-T with Concurrent vs Sequential Enzalutamide in mCRPC
NCT01981122Phase 2Completed
- Sponsor
- Dendreon
- Start
- Sep 2013
- Primary completion
- Jun 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Dendreon. Started Sep 2013; status: completed.
02
Drugs
sipuleucel-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01981122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01981122.